Streetbeat News

Regulatory

AIMD

Ainos shares rise following approval from the National Taiwan University Hospital's Institutional Review Board for a clinical trial on treating oral warts in HIV-positive patients.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:14 pm

BTCUSD

Bill Maher criticizes Bitcoin mining for its high energy consumption, claiming it undermines green energy progress. He compares its environmental impact to adding millions of gas-powered cars. The debate on crypto's carbon footprint is intensifying.

Portfolio Pulse from Murtuza Merchant

September 25, 2024 | 12:10 pm

AIMD

Ainos has received IRB approval from National Taiwan University Hospital for a clinical trial of its FDA-designated orphan drug VELDONA, targeting HIV-related oral warts. The company is awaiting Taiwan FDA approval to commence the trial.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:09 pm

PALI

Palisade Bio is progressing towards the launch of a Phase 1 clinical study for its lead program, PALI-2108, aimed at treating ulcerative colitis. The company has completed necessary preclinical studies and is on track to initiate clinical site and dosing by year-end.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:08 pm

HRTX

Heron Therapeutics' stock is rising following the FDA's approval of its Prior Approval Supplement application for the ZYNRELEF vial access needle.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:07 pm

HRTX

Heron Therapeutics has received FDA approval for its Prior Approval Supplement Application for the ZYNRELEF Vial Access Needle, which could enhance the product's marketability and usage.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:06 pm

DRRX

DURECT has announced the design for a Phase 3 trial of Larsucosterol in treating alcohol-associated hepatitis. The trial, agreed upon with the FDA, will enroll 200 U.S. patients and focus on a 90-day survival endpoint. Results are expected within two years.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:02 pm

DE

Former President Donald Trump has proposed a 200% tariff on John Deere for moving production to Mexico, drawing criticism from trade economists and entrepreneur Mark Cuban. Experts argue the tariff could harm the company and is not supported by respected economists.

Portfolio Pulse from Pooja Rajkumari

September 25, 2024 | 11:52 am

ACST

Acasti Pharma has completed patient enrollment for its Phase 3 STRIVE-ON safety trial, which is a significant milestone in the development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:34 am

IFRX

InflaRx announced the presentation of a post hoc analysis of its Phase 2b study on Vilobelimab, an anti-c5a antibody, at the 2024 European Academy of Dermatology and Venereology Congress. This study focuses on its application in treating Hidradenitis Suppurativa.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 11:33 am